Key result
Tocilizumab attenuates inflammation and reduces troponin T release versus placebo in NSTEMI patients.
Why the study?
Does a single dose of tocilizumab reduce inflammation and troponin T release in patients with NSTEMI?
Does a single dose of tocilizumab reduce inflammation and troponin T release in patients with NSTEMI?
Answers are grounded in this paper and cite their sources.
A single dose of tocilizumab attenuates inflammation and PCI-related troponin T release in patients with NSTEMI.
Tocilizumab attenuated the inflammatory response and primarily PCI-related TnT release in NSTEMI patients.
No takes yet. Share an insight, caveat, or question.
Kleveland et al. (2016) studied this question. Tocilizumab attenuated the inflammatory response and reduced troponin T release in NSTEMI patients compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: